Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ReWalk Robotics Ltd (LFWD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: LFWD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.67
1 Year Target Price $8.67
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.19% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.55M USD | Price to earnings Ratio - | 1Y Target Price 8.67 |
Price to earnings Ratio - | 1Y Target Price 8.67 | ||
Volume (30-day avg) 3 | Beta 0.1 | 52 Weeks Range 0.50 - 4.00 | Updated Date 08/15/2025 |
52 Weeks Range 0.50 - 4.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.2733 | Actual -0.31 |
Profitability
Profit Margin -121.8% | Operating Margin (TTM) -66.04% |
Management Effectiveness
Return on Assets (TTM) -28.68% | Return on Equity (TTM) -114.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4439586 | Price to Sales(TTM) 0.39 |
Enterprise Value 4439586 | Price to Sales(TTM) 0.39 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA 1.04 | Shares Outstanding 15602300 | Shares Floating 11024153 |
Shares Outstanding 15602300 | Shares Floating 11024153 | ||
Percent Insiders 2.8 | Percent Institutions 3.22 |
Upturn AI SWOT
ReWalk Robotics Ltd
Company Overview
History and Background
ReWalk Robotics Ltd. was founded in 2001. It focuses on developing and marketing exoskeletons that enable individuals with spinal cord injuries or other mobility impairments to stand and walk again. Key milestones include FDA clearance for its ReWalk Personal System and ReWalk Rehabilitation System.
Core Business Areas
- Personal Exoskeletons: Design, development, and marketing of exoskeletons for personal use by individuals with spinal cord injuries, allowing them to stand and walk independently.
- Rehabilitation Exoskeletons: Manufacture and distribution of exoskeletons for use in rehabilitation centers to aid in gait training and therapy for patients with mobility impairments.
Leadership and Structure
Larry Jasinski is the CEO. The company has a board of directors and operates with functional departments including R&D, Sales & Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- ReWalk Personal System: An exoskeleton designed for daily use by individuals with spinal cord injuries, enabling them to stand, walk, and climb stairs. Market share information is difficult to pinpoint exactly but estimated to be around 25-35% of the powered exoskeleton market. Competitors include Ekso Bionics and Parker Hannifin (Indego).
- ReWalk Rehabilitation System: An exoskeleton used in rehabilitation centers to facilitate gait training and therapy for patients with mobility impairments. Competitors include Ekso Bionics and Hocoma.
Market Dynamics
Industry Overview
The exoskeleton market is growing, driven by technological advancements, increasing awareness of the benefits of exoskeletons for rehabilitation and mobility, and an aging population. Government regulations and reimbursement policies influence the market growth.
Positioning
ReWalk Robotics is a key player in the powered exoskeleton market, focusing on solutions for spinal cord injury patients. Its competitive advantages include established brand recognition and regulatory approvals.
Total Addressable Market (TAM)
The global exoskeleton market is projected to reach billions of dollars in the coming years. ReWalk Robotics Ltd is positioned to capture a portion of this TAM through its established products and focus on spinal cord injury solutions.
Upturn SWOT Analysis
Strengths
- Established brand recognition
- Regulatory approvals (FDA clearance)
- Focus on spinal cord injury segment
- Experienced leadership team
Weaknesses
- Limited product portfolio
- High product cost
- Dependence on reimbursement policies
- History of operating losses
Opportunities
- Expanding into new markets (e.g., stroke rehabilitation)
- Developing next-generation exoskeleton technology
- Securing favorable reimbursement policies
- Partnerships with healthcare providers
Threats
- Intense competition
- Technological obsolescence
- Unfavorable reimbursement policies
- Economic downturn
Competitors and Market Share
Key Competitors
- EKSO
- OTC:PARKF
- Myomo (MYO)
Competitive Landscape
ReWalk Robotics competes with other exoskeleton manufacturers based on product features, price, reimbursement coverage, and brand reputation. ReWalk has an advantage in FDA approved devices.
Growth Trajectory and Initiatives
Historical Growth: Growth has been uneven, with periods of rapid expansion followed by slower growth. Access to historical revenue data is needed to quantify this.
Future Projections: Analyst estimates suggest potential for future growth driven by expanding market adoption and new product development. These figures vary.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts, pursuing new reimbursement agreements, and developing next-generation exoskeleton technology.
Summary
ReWalk Robotics is a key player in the exoskeleton market, holding a good portion of the market share within its industry. The company's financial state is not doing well, and it will need to focus on lowering costs while at the same time growing revenues. The company's strengths lie in its products and regulatory approvals. They need to capitalize on new market opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and represents an opinion. It is not financial advice. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ReWalk Robotics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-09-12 | President, CEO & Director Mr. William Mark Grant | ||
Sector Healthcare | Industry Medical Devices | Full time employees 80 | Website https://golifeward.com |
Full time employees 80 | Website https://golifeward.com | ||
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.